Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 200 #1
CompanyOvaScience, Inc.
Market Cap1.05BEPS (ttm)-2.01
P/E-EPS this Y22.70%
Forward P/E-EPS next Y17.90%
PEG-EPS past 5Y0.00%
P/S-EPS next 5Y-
P/B14.96EPS Q/Q-35.00%
Dividend-Sales Q/Q-
Insider Own17.10%Inst Own76.70%
Insider Trans-18.56%Inst Trans-1.66%
Short Float6.55%EarningsNov 11
Analyst Recom2.00Target Price34.20
Avg Volume199.35K52W Range5.51 - 36.54
Dec-18-14Reiterated H.C. Wainwright Buy $40 → $100
Dec-18-14 12:29PMOvaScience Shares Could Reach $47 at
Dec-18-14 11:01AMWhy OvaScience Shares Soared 35% Benzinga
Dec-17-14 09:01AMOVASCIENCE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Dec-17-14 07:03AM7:03 am OvaScience announced that it has achieved its 2014 corporate goals to advance the AUGMENTSM, OvaPrimeSM and OvaTureSM treatments for patients in need of new fertility treatment options
Dec-17-14 07:00AMOvaScience Advances All Three Fertility Treatment Options Business Wire
Dec-12-14 10:03AMOvaScience (OVAS) is Overbought: Is A Drop Coming? Zacks
Dec-12-14 08:30AMOvaScience to Host Investor Day Business Wire
Dec-11-14 05:10PMOVASCIENCE, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors or Principal Officer EDGAR Online
Dec-11-14 08:30AMOvaScience Strengthens Management Team to Support Expanding Global Operations Business Wire
Dec-10-14 12:01AMOvaScience's Blistering Run Has More Life in It at
OvaScience, Inc., a life sciences company, is engaged in the discovery, development, and commercialization of new treatments for infertility. The company's patented technology is based on the discovery of egg precursor cells (EggPCs), which are found in the ovaries. It is developing various fertility treatment options designed to enhance egg quality and in vitro fertilization (IVF) comprising AUGMENT to improve egg quality and increase the success of IVF by transferring mitochondria from a woman's EggPCs to her mature egg during IVF; OvaPrime for boosting a woman's egg reserve by transferring the EggPCs from the outer layer of her ovary back into the ovary prior to IVF; OvaTure to create mature fertilizable eggs from a woman's own EggPCs without the need for hormone injections; and OvaXon to develop an approach to the prevention of genetic disease and animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dipp MichellePresident and CEONov 24Buy24.533007,359807,668Nov 26 08:06 AM
Stock Harald F.DirectorSep 23Buy14.225227,42413,022Sep 25 08:45 AM
Stock Harald F.DirectorAug 26Buy12.995807,53412,500Aug 28 08:32 AM
Stock Harald F.DirectorAug 12Buy11.026787,46811,920Aug 14 08:30 AM
Stock Harald F.DirectorJul 29Buy8.988307,45311,242Jul 31 08:15 AM
CompanyTetraphase Pharmaceuticals, Inc.
IndustryDrug Manufacturers - Major
Market Cap1.17BEPS (ttm)-2.27
P/E-EPS this Y96.30%
Forward P/E-EPS next Y10.20%
PEG-EPS past 5Y0.00%
P/S147.48EPS next 5Y-
P/B21.71EPS Q/Q-12.20%
Dividend-Sales Q/Q4.50%
Insider Own0.40%Inst Own65.10%
Insider Trans-88.70%Inst Trans-0.41%
Short Float6.79%EarningsNov 12/a
Analyst Recom1.50Target Price27.80
Avg Volume617.00K52W Range8.01 - 33.22
Dec-18-14Reiterated Brean Capital Buy $23 → $50
Dec-18-14Reiterated Stifel Buy $28 → $54
Dec-18-14Reiterated Needham Buy $28 → $46
Dec-18-14 11:54AMTetraphase Jumps As 'Superbug' Drug Scores In Trial at Investor's Business Daily
Dec-18-14 10:14AMTetraphase soars after releasing clinical trial results AP
Dec-17-14 04:01PM4:01 pm Tetraphase Pharmaceuticals announces positive top-line results from Phase 3 IGNITE 1 clinical trial of Eravacycline in complicated intra-abdominal infections; achieves primary endpoint in first of two pivotal trials
Dec-17-14 04:01PMTetraphase Announces Positive Top-line Results from Phase 3 IGNITE 1 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections Business Wire
Dec-15-14 08:18AMTetraphase Pharmaceuticals Added to NASDAQ Biotechnology Index Business Wire
Dec-09-14 05:52AMTetraphase Pharmaceuticals (TTPH) Jumps: Stock Up 8.8% Zacks
Dec-04-14 07:00AMTetraphase Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference Business Wire
Dec-01-14 08:27AMCan The Uptrend Continue for Tetraphase (TTPH)? Zacks
Nov-21-14 06:08PMTetraphase Said to Explore Sale After Takeover Interest at Bloomberg
Nov-18-14 01:04PMTETRAPHASE PHARMACEUTICALS INC Financials EDGAR Online Financials
Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections. Its lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative bacteria. The company is conducting a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and a second Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to-oral step-down therapy. It is also developing TP-271, a preclinical compound for respiratory diseases caused by bacterial biothreat pathogens; and preclinical Gram-negative program for multidrug-resistant Gram-negative infections. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Freund John GordonDirectorOct 02Sale20.94105,5882,211,146890,146Oct 03 05:01 PM
Freund John GordonDirectorOct 01Sale20.84142,1462,962,731995,734Oct 03 05:01 PM
Freund John GordonDirectorSep 30Sale20.1756,6181,141,8441,137,880Oct 01 04:08 PM
Freund John GordonDirectorSep 29Sale20.1995,6481,931,3341,194,498Oct 01 04:08 PM
Macdonald GuyPresident and Chief ExecutiveSep 23Option Exercise2.0310,00020,30060,000Sep 25 04:23 PM
TickerOCC [NASD]
CompanyOptical Cable Corp.
IndustryCommunication Equipment
Market Cap32.43MEPS (ttm)-0.06
P/E-EPS this Y-102.30%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-15.20%
P/S0.42EPS next 5Y-
P/B0.95EPS Q/Q400.00%
Dividend1.69%Sales Q/Q-62.50%
Insider Own15.90%Inst Own14.50%
Insider Trans-2.15%Inst Trans-1.48%
Short Float0.03%EarningsDec 18/b
Analyst Recom-Target Price-
Avg Volume5.64K52W Range3.52 - 5.00
Dec-18-14 08:00AMOptical Cable Corporation Reports Fourth Quarter and Fiscal Year 2014 Financial Results PR Newswire
Dec-18-14 07:07AMQ4 2014 Optical Cable Corp Earnings Release - Before Market Open CCBN
Dec-16-14 06:15PMOptical Cable Corporation Schedules Conference Call To Discuss Fourth Quarter Of Fiscal Year 2014 Results PR Newswire
Oct-16-14 01:30PMOPTICAL CABLE CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Oct-16-14 08:00AMOptical Cable Corporation Declares Quarterly Dividend PR Newswire
Oct-02-14 11:01AMOCC® Introduces Industry's First Next Generation Category 8 Connector PR Newswire
Sep-17-14 01:04PMOPTICAL CABLE CORP Financials EDGAR Online Financials
Sep-11-14 02:34PMOPTICAL CABLE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi EDGAR Online
Sep-10-14 12:27PMOPTICAL CABLE CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
Sep-10-14 11:00AMOptical Cable Corp Earnings Call scheduled for 11:00 am ET today CCBN
Optical Cable Corporation, together with its subsidiaries, manufactures and sells fiber optic and copper data communications cabling and connectivity solutions for the enterprise market in the United States and internationally. The company markets and sells various copper datacom cables, including unshielded and shielded twisted pair. It also offers fiber optic connectivity products, including fiber optic wall mounts, cabinet mount and rack mount enclosures, pre-terminated fiber optic enclosures, fiber optic connectors, splice trays, fiber optic jumpers, plug and play cassette modules, pre-terminated fiber optic cable assemblies, adapters, and accessories. In addition, the company provides copper connectivity products comprising category compliant patch panels, jacks, plugs, patch cords, faceplates, surface mounted boxes, distribution and multi-media boxes, copper rack mount and wall mount enclosures, cable assemblies, cable organizers, and other wiring products for datacenter, telecommunications closet, equipment room, and workstation applications. Further, it offers network, data storage, and telecommunications management systems, such as data cabinets, wall-mount enclosures, cable management systems, and open frame relay racks for commercial and residential use; various enclosures, modules, and modular outlets for single dwelling and multiple dwelling residential uses; and cellular distribution system, a distributed antenna system for in-building enhancement of wireless communications signals. Additionally, the company provides applied interconnect systems, which include specialty fiber optic connectors and connectivity components, ruggedized copper datacom connectors, and related systems and solutions for military and harsh environment applications. The company sells its products to distributors, original equipment manufacturers, value-added resellers, and end-users. Optical Cable Corporation was founded in 1983 and is headquartered in Roanoke, Virginia.
CompanyInogen, Inc.
IndustryMedical Instruments & Supplies
Market Cap545.30MEPS (ttm)0.65
P/E45.03EPS this Y103.40%
Forward P/E74.29EPS next Y32.21%
PEG2.05EPS past 5Y0.00%
P/S5.28EPS next 5Y22.00%
P/B4.70EPS Q/Q102.80%
Dividend-Sales Q/Q48.50%
Insider Own19.70%Inst Own89.20%
Insider Trans-54.68%Inst Trans4.56%
Short Float1.75%EarningsAug 12/a
Analyst Recom1.60Target Price33.33
Avg Volume124.28K52W Range13.12 - 26.97
Dec-18-14 08:09PMNasdaq stocks posting largest percentage increases AP
Dec-15-14 08:00AMInogen Discusses Oxygen Therapy Market and Future Growth Drivers at Investor/Analyst Day GlobeNewswire
Dec-15-14 06:05AMINOGEN INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Dec-12-14 11:20AMInogen Leases Texas Facility, Lower Costs to Drive Growth Zacks
Dec-05-14 05:30PMINOGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
Dec-05-14 04:05PMInogen Expands Manufacturing Capacity to Accommodate Growth GlobeNewswire
Dec-01-14 04:05PMInogen Announces Investor/Analyst Day and Webcast GlobeNewswire
Nov-21-14 01:04PMINOGEN INC Financials EDGAR Online Financials
Nov-13-14 08:00AMInogen Recognized as One of the Fastest Growing Companies in North America According to Deloitte's 2014 Technology Fast 500(TM) GlobeNewswire
Nov-12-14 07:31AMINOGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic obstructive pulmonary disease and other chronic respiratory conditions. It offers Inogen One systems, which are portable devices that concentrate the air around them to offer a single source of supplemental oxygen; and related accessories to patients, insurance carriers, home healthcare providers, and distributors. The company sells its products in the United States and internationally. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wilkinson ScottEVP, Sales and MarketingDec 11Option Exercise0.6014,7008,82014,700Dec 12 04:53 PM
Wilkinson ScottEVP, Sales and MarketingDec 11Sale25.2514,700371,1040Dec 12 04:53 PM
Wilkinson ScottEVP, Sales and MarketingDec 10Option Exercise0.60300180300Dec 11 04:14 PM
Wilkinson ScottEVP, Sales and MarketingDec 10Sale25.153007,5450Dec 11 04:14 PM
Scribner MattEVP, OperationsDec 03Option Exercise0.604,1022,4618,768Dec 04 04:07 PM
TickerODP [NASD]
CompanyOffice Depot, Inc.
IndustrySpecialty Retail, Other
Market Cap4.52BEPS (ttm)-0.85
P/E-EPS this Y25.60%
Forward P/E18.28EPS next Y149.46%
PEG-EPS past 5Y44.30%
P/S0.29EPS next 5Y-
P/B2.73EPS Q/Q-87.80%
Dividend-Sales Q/Q55.40%
Insider Own0.20%Inst Own95.20%
Insider Trans43.97%Inst Trans-2.30%
Short Float5.36%EarningsNov 04/b
Analyst Recom2.60Target Price7.45
Avg Volume10.63M52W Range3.84 - 8.06
Dec-18-14 01:16PMConstantly changing online prices stump shoppers AP
Dec-16-14 03:00PMOffice Depot, Inc. Announces Deals for Last-Minute Holiday Shoppers Business Wire
Dec-16-14 09:52AMOffice Depot upgraded by BB&T Capital Mkts
Dec-15-14 01:28PMOffice Depot (ODP) Stock Climbs Today Following Staples Purchase Speculation at TheStreet
Dec-15-14 01:05PMB Riley & Co's Scott Tilghman On Possibility Of Staples, Office Depot Merger: 'There's A Lot Of Cost-Savings To Be Had There' Benzinga
Dec-15-14 01:00PMB Riley & Co Analyst Scott Tilghman: Staples CEO Has Been Public About Dislike For Office Depot Benzinga
Dec-15-14 10:40AMOffice Depot Now a Strong Buy, Merger Speculations Rife Zacks
Dec-15-14 10:24AMCan the Rally in Office Depot (ODP) Shares Continue? Zacks
Dec-12-14 04:35PMShares of Office Depot Rise as Starboard Discloses 9.9% Stake Zacks
Dec-12-14 01:56PMCiti: FTC Won't Allow Merger Of Staples, Office Depot Benzinga
Office Depot, Inc., together with its subsidiaries, supplies office products and services. The company's North American Retail division sells an assortment of merchandise, including office supplies, technology products and solutions, business machines and related supplies, facilities products, and office furniture under various brands through its chain of office supply stores. Its North American Business Solutions division sells branded office supplies, technology products, cleaning and breakroom supplies, office furniture, services, and other solutions, as well as copy and print services to small, medium, and large-sized businesses through a sales force, catalogs, telesales, Internet sites, and limited store locations. The company's International division sells office products and services through direct mail catalogs, contract sales forces, Internet sites, and retail stores using company-owned operations, joint ventures, licensing and franchise agreements, alliances, and other arrangements. This division also participates under licensing and merchandise arrangements in South Korea, Israel, the Dominican Republic, and the Middle East. It offers its products under various labels, including Office Depot, OfficeMax, Viking Office Products, Foray, Ativa, Grand & Toy, TUL, and DiVOGA. As of February 25, 2014, the company operated 2,200 retail stores in 57 countries. Office Depot, Inc. was founded in 1986 and is headquartered in Boca Raton, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Garcia C Elisa DEVP-Chief Legal Officer & SecyAug 18Sale5.1511,53159,327400,512Aug 20 04:56 PM
Garcia C Elisa DEVP-Chief Legal Officer & SecyMay 21Sale5.0122,097110,706412,043May 22 06:24 PM
JAMISON CYNTHIA TDirectorMay 14Sale5.509,48852,18416,461May 15 05:21 PM
VASSALLUZZO JOSEPHDirectorMar 14Buy4.5815,00068,70060,034Mar 14 03:40 PM
BRYANT WARREN FDirectorMar 13Buy4.666,00027,953218,831Mar 14 03:41 PM
CompanySynergetics USA, Inc.
IndustryMedical Appliances & Equipment
Market Cap108.50MEPS (ttm)0.12
P/E35.67EPS this Y20.00%
Forward P/E18.21EPS next Y59.86%
PEG2.97EPS past 5Y11.40%
P/S1.67EPS next 5Y12.00%
P/B1.69EPS Q/Q0.00%
Dividend-Sales Q/Q0.60%
Insider Own0.30%Inst Own52.60%
Insider Trans38.15%Inst Trans8.21%
Short Float0.10%EarningsJun 10
Analyst Recom1.30Target Price6.50
Avg Volume50.45K52W Range2.93 - 4.05
Dec-17-14 05:04PMSYNERGETICS USA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Ob EDGAR Online
Dec-17-14 01:04PMSYNERGETICS USA INC Financials EDGAR Online Financials
Dec-15-14 07:03AMSynergetics USA (SURG) Jumps: Stock Adds 9.1% in Session Zacks
Dec-12-14 07:07PM10-Q for Synergetics USA, Inc. Company Spotlight
Dec-12-14 06:01AMSYNERGETICS USA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Dec-10-14 05:05PMSYNERGETICS USA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disp EDGAR Online
Dec-10-14 04:48PMSynergetics posts 1Q profit AP
Dec-10-14 04:18PMSYNERGETICS USA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Dec-10-14 04:05PMSynergetics Reports First Quarter of Fiscal Year 2015 Results Marketwired
Dec-10-14 04:01PMSynergetics Acquires U.K.-Based Manufacturer Sterimedix Ltd. Marketwired
Synergetics USA, Inc., a medical device company, provides precision surgical devices, surgical equipment, and consumables primarily for the ophthalmology and neurosurgery markets in the United States and internationally. The company's product lines focuses upon precision engineered disposable and reusable devices, surgical equipment, procedural kits, and the delivery of various energy modalities, including laser energy, ultrasonic energy, radio frequency energy for electro surgery and lesion generation, and visible light energy for illumination. It offers approximately 1,000 separate catalogue items in the vitreoretinal surgical market, including vitrectomy system under the VersaVIT 2.0 brand; procedural packs under VersaPACK and Core Essentials brands; fiberoptic endoilluminators and endolaser probes; various disposable and reusable devices designed for intraocular manipulation of tissues; illumination equipment under the Photon brand; laser equipment for the United States market under Ellex's Solitaire brand; Volk's line of ophthalmic lenses; Labtician's scleral buckles; and other miscellaneous products. The company sells its products directly, as well as through distributors and independent sales representatives to end-users at hospitals, ambulatory surgery centers, and surgeon offices. Synergetics USA, Inc. is headquartered in O'Fallon, Missouri.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thomas David GraemeDirectorOct 20Buy3.371,0003,3723,000Oct 21 03:11 PM
GUARCH GUY RDirectorJun 18Option Exercise1.3710,00013,70026,000Jun 19 12:58 PM
DICK ROBERT HDirectorJun 16Option Exercise0.9010,0009,00053,000Jun 17 10:55 AM
Hable David MPresident and CEOMar 26Buy3.043,2579,905110,195Mar 27 10:24 AM
Thomas David GraemeDirectorMar 21Buy3.071,0003,0742,000Mar 24 11:06 AM
CompanyNeurocrine Biosciences Inc.
IndustryDrugs - Generic
Market Cap1.82BEPS (ttm)-0.71
P/E-EPS this Y-962.50%
Forward P/E-EPS next Y6.10%
PEG-EPS past 5Y21.40%
P/S2594.86EPS next 5Y16.44%
P/B8.10EPS Q/Q-23.50%
Dividend-Sales Q/Q-
Insider Own0.60%Inst Own97.90%
Insider Trans-5.59%Inst Trans4.04%
Short Float9.01%EarningsNov 03/a
Analyst Recom1.90Target Price23.17
Avg Volume637.45K52W Range8.87 - 22.56
Dec-17-14 12:00PMASPX: Auspex Pharma Hits A Homerun In Phase 3 Huntington's Chorea Trial Zacks Small Cap Research
Dec-11-14 10:25AMNeurocrine draws bearish trade optionMONSTER
Dec-10-14 08:00AMNeurocrine Biosciences Announces Expansion of its Clinical Pipeline PR Newswire
Dec-04-14 07:00PMNeurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference PR Newswire
Nov-25-14 01:00PMNeurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-12-14 01:56PMNeurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference PR Newswire
Nov-11-14 01:04PMNEUROCRINE BIOSCIENCES INC Financials EDGAR Online Financials
Nov-06-14 07:08PM10-Q for Neurocrine Biosciences, Inc. Company Spotlight
Nov-04-14 12:58PMNEUROCRINE BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-04-14 11:30AM2015 Packed With Catalysts For Neurocrine Bio Zacks Small Cap Research
Neurocrine Biosciences, Inc. discovers, develops, and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development stage include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for tourette syndrome schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men's and women's health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grigoriadis Dimitri E.Chief Research OfficerDec 15Option Exercise5.122,50012,80079,558Dec 15 07:24 PM
Bozigian Haig P.Chief Development OfficerDec 15Option Exercise5.122,50012,80081,079Dec 15 07:26 PM
Grigoriadis Dimitri E.Chief Research OfficerDec 15Sale21.712,50054,27577,058Dec 15 07:24 PM
Bozigian Haig P.Chief Development OfficerDec 15Sale21.722,50054,30078,579Dec 15 07:26 PM
Gano KyleChief Business Dev OfficerDec 12Option Exercise5.004,04320,21527,781Dec 15 07:22 PM
CompanyXencor, Inc.
Market Cap511.66MEPS (ttm)-1.11
P/E-EPS this Y82.90%
Forward P/E-EPS next Y-13.60%
PEG-EPS past 5Y0.00%
P/S91.37EPS next 5Y-
P/B8.58EPS Q/Q-33.30%
Dividend-Sales Q/Q-75.00%
Insider Own0.10%Inst Own42.80%
Insider Trans-92.74%Inst Trans4.95%
Short Float2.01%EarningsJul 31/a
Analyst Recom1.40Target Price17.80
Avg Volume64.04K52W Range7.77 - 15.95
Dec-18-14 08:00AMXencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb Bispecific and Immune Inhibitor Technologies PR Newswire
Dec-06-14 11:03PMMorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting Thomson Reuters ONE
Dec-06-14 11:00PMMorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting PR Newswire
Dec-04-14 08:00AMXencor to Present at the 25th Annual Oppenheimer & Co. Healthcare Conference PR Newswire
Nov-25-14 08:00AMXencor to Present at the 2014 Deutsche Bank BioFEST Conference PR Newswire
Nov-18-14 01:04PMXENCOR INC Financials EDGAR Online Financials
Nov-10-14 04:55PMXENCOR INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
Nov-10-14 04:01PMXencor Reports Third Quarter 2014 Financial Results PR Newswire
Nov-06-14 09:09AMXencor Provides Data Updates on XmAb Bispecific Antibody Programs and Announces Presentations at Upcoming American Society of Hematology 2014 Annual Meeting PR Newswire
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through its proprietary XmAb technology platform. The company's lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor under Phase Ib clinical trial initiation to treat asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate that is in Phase II clinical trials for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STAFFORD JOHN S IIIDirectorAug 11Sale9.37124,0001,161,88027,638Aug 13 02:45 PM
TickerORCL [NYSE, S&P 500]
CompanyOracle Corporation
IndustryApplication Software
Market Cap200.96BEPS (ttm)2.39
P/E18.97EPS this Y5.30%
Forward P/E13.81EPS next Y7.96%
PEG2.07EPS past 5Y16.90%
P/S5.22EPS next 5Y9.15%
P/B4.26EPS Q/Q2.10%
Dividend1.06%Sales Q/Q2.70%
Insider Own25.05%Inst Own60.50%
Insider Trans0.00%Inst Trans-1.12%
Short Float1.03%EarningsDec 17/a
Analyst Recom2.50Target Price43.53
Avg Volume15.54M52W Range33.29 - 42.94
Dec-18-14Reiterated FBR Capital Outperform $46 → $48
Dec-18-14Reiterated BMO Capital Markets Outperform $45 → $49
Dec-18-14Reiterated Canaccord Genuity Buy $48 → $50
Dec-18-14Reiterated Deutsche Bank Hold $42 → $44
Dec-18-14 06:08PMBiz Break: Oracle soars to new high as Wall Street rebound continues at San Jose Mercury News
Dec-18-14 06:00PMCramer bakes a bull cake CNBC
Dec-18-14 04:58PMUS STOCKS-Wall St has best 2-day gain since 2011 on Fed optimism Reuters
Dec-18-14 04:47PMOracle: a chance of cloud at Financial Times
Dec-18-14 04:24PMThe Top Ten Stocks for Dec. 18 at Bloomberg
Dec-18-14 04:19PMOracle Conference Call Highlights Benzinga
Dec-18-14 03:01PMOracle Up 8% as Ellison Crows about Cloud; Targets Going Up as Estimates Trimmed at
Dec-18-14 02:22PMOracle Analyst Roundup After Q2 Earnings Benzinga
Dec-18-14 02:21PMOracle on fire after success in the cloud at Financial Times
Dec-18-14 01:09PMOracle rains on Salesforce and Workday in cloud computing at MarketWatch
Oracle Corporation develops, manufactures, markets, hosts, and supports database and middleware software, application software, cloud infrastructure, hardware systems, and related services worldwide. It provides software and hardware systems, and related services to manage their cloud-based or on-premise IT environments, as well as to deploy cloud software-as-a-service, platform-as-a-service, and infrastructure-as-a-service. The company offers software for mobile computing; database and middleware software that runs and manages business applications for midsize businesses and large enterprises; and Java, a software development language. It also provides applications software, such as human capital and talent management, customer experience and customer relationship management, financial management and governance, risk and compliance, procurement, project portfolio management, supply chain management, business analytics and enterprise performance management, and industry-specific applications software; and virtual machine instance, hardware and related support, and software and hardware management and maintenance services. In addition, the company offers customers with rights to software product upgrades and maintenance releases; patches released; and Internet access to technical content, as well as Internet and telephone access to technical support personnel. Further, it provides servers, storage, networking, virtualization software, operating systems, and management software to support various IT environments; and hardware systems support solutions, such as software updates for the software components. Additionally, the company offers consulting services, such as IT strategy alignment, enterprise architecture planning and design, initial product implementation and integration, and ongoing product enhancement and upgrade; customer support services; and education services. Oracle Corporation was founded in 1977 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GARCIA-MOLINA HECTORDirectorDec 15Option Exercise13.422,96039,7097,960Dec 16 01:46 PM
GARCIA-MOLINA HECTORDirectorDec 15Sale41.062,960121,5385,000Dec 16 01:46 PM
HENLEY JEFFREYChairman of the BoardNov 28Option Exercise12.34500,0006,170,000500,000Dec 02 02:35 PM
BOSKIN MICHAEL JDirectorNov 28Option Exercise14.0250,000701,00055,000Dec 02 02:45 PM
HENLEY JEFFREYChairman of the BoardNov 28Sale42.09500,00021,047,3500Dec 02 02:35 PM
CompanyCempra, Inc.
Market Cap735.08MEPS (ttm)-1.85
P/E-EPS this Y-24.40%
Forward P/E-EPS next Y14.40%
PEG-EPS past 5Y-11.70%
P/S49.67EPS next 5Y-
P/B17.68EPS Q/Q17.10%
Dividend-Sales Q/Q550.00%
Insider Own46.75%Inst Own76.10%
Insider Trans0.08%Inst Trans3.06%
Short Float8.38%EarningsOct 29/a
Analyst Recom1.40Target Price20.00
Avg Volume407.80K52W Range8.10 - 19.61
Dec-11-14 08:21AMWill Cempra (CEMP) Continue to Surge Higher? Zacks
Dec-09-14 07:00AMCempra (CEMP) in Focus: Stock Rises 11.4% in Session Zacks
Dec-03-14 04:10PMCempra to Participate in Upcoming Investor Events in December GlobeNewswire
Nov-19-14 08:11AMCEMPRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
Nov-19-14 06:00AMCempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies GlobeNewswire
Nov-10-14 04:05PMCempra to Present at Two Upcoming Investor Conferences GlobeNewswire
Nov-06-14 08:11AMMoving Average Crossover Alert: Cempra (CEMP) Zacks
Nov-06-14 05:55AMWhy Cempra (CEMP) Could Be Positioned for a Surge? Zacks
Nov-05-14 01:04PMCEMPRA, INC. Financials EDGAR Online Financials
Nov-04-14 05:16AMMoving Average Crossover Alert: Cempra (CEMP) Zacks
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases in North America. Its two lead product candidates include Solithromycin (CEM-101), which is in a Phase III clinical trial for community-acquired bacterial pneumonia (CABP); and TAKSTA (CEM-102) that is in a Phase II clinical trial for prosthetic joint infections. The company also focuses on using its series of proprietary lead compounds from its novel macrolide library for uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHNSON JOHNDirectorMay 23Buy9.1010,00090,98010,000May 28 05:23 PM
Fernandes PrabhavathiPresident and CEOMay 14Option Exercise1.4312,10517,310219,289May 15 04:46 PM
1 2 3 4 5 6 ... 10 ... 20 next